FDA Approves Subcutaneous Lecanemab for Early Alzheimer's Treatment

Why it matters locally: The approval of at-home administered Lecanemab could significantly impact the approximately 150,000 Virginians aged 65 and older living with Alzheimer's, potentially improving access to treatment for early-stage patients across the state.

---

The Food and Drug Administration (FDA) has granted approval for LEQEMBI IQLIK (lecanemab-irmb), a subcutaneous injection intended for individuals with early Alzheimer's disease. This new formulation allows for administration at home. LEQEMBI IQLIK serves as an anti-amyloid treatment. The approval specifically covers its use as an initiation dose. This marks the first time a treatment for early Alzheimer's disease has received approval for at-home, subcutaneous initiation and maintenance dosing. Patients can administer LEQEMBI IQLIK at home, following initial guidance from healthcare providers. The at-home administration method aims to provide greater convenience for eligible individuals and their caregivers. Physicians will continue to assess patient suitability for this treatment.